iPharma Center
@ipharma_center
Followers
0
Following
318
Media
1
Statuses
343
Business account of iPharmaCenter. Please DM for business related messages
Joined March 2023
#CMS launched the 10-year #ACCESSModel in Original #Medicare to test outcome-aligned payments and tech-enabled care for high-burden chronic conditions https://t.co/lOXF6vsB6O
#CMS #Medicare #news #Trump #BreakingNews #Hypertension #Diabetes #Depression #PresidentTrump #media
ipharmacenter.com
CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported...
0
2
5
#CMS launched ACCESS Model in the #UnitedStates
https://t.co/2210BnD2A0
#pharma #pharmaceutical #Trump #PresidentTrump #Medicaid #Medicare #DigitalHealth #PopulationHealth #USNews #USA
ipharmacenter.com
CMS has introduced the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a new 10‑year voluntary payment model in Original Medicare designed to expand technology‑supported...
#CMS launched the 10-year #ACCESSModel in Original #Medicare to test outcome-aligned payments and tech-enabled care for high-burden chronic conditions https://t.co/lOXF6vsB6O
#CMS #Medicare #news #Trump #BreakingNews #Hypertension #Diabetes #Depression #PresidentTrump #media
0
0
0
Find the latest #China's #pharmaceutical updates like never before on
ipharmacenter.com
iPharmaCenter has #pharmaceutical and #healthcare #news, #blogs, #industry updates. We provide news on approvals, acquisitions. #Blogs on healthcare and pharmaceutical industry. We cover updates...
#China’s #NMPA has approved #Pfizer’s recombinant mAb #matazisimab as the first prophylactic option for #hemophilia A or B patients ≥12 years with FVIII/IX inhibitors https://t.co/uZbN8aLciq
#hemophilia #bleedingdisorders #pharma #HemeTwitter #OncoTwitter #OncoAlert #OncoAlerts
0
0
0
Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology
ipharmacenter.com
BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor...
Find the list of top #pharmaceutical companies by revenues in 2025 https://t.co/R1j2nd53jX
#pharma #pharmaceutical #trump #presidenttrump #Medicare #Medicaid #CMS #healthcare #neurology #oncology #rheumatology #SABCS25 #news #media #top10
0
0
0
Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology
ipharmacenter.com
BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor...
#Imfinzi + FLOT is now FDA-approved as the first perioperative #immunotherapy for resectable stage II–IVA gastric and GEJ cancers, based on positive MATTERHORN data https://t.co/Z429ApBtF8
#news #media #gastriccancer #GEJcancer #Immunotherapy #OncoTwitter #OncoAlert #OncoAlerts
0
0
0
Follow #SABCS25 and ASH25 on #ipharmacenter for continuous updates https://t.co/jr5sYZhYPf
#pharma #pharmaceutical #healthcare #globalhealth #cancer #oncology #cancerresearch #OncoTwitter #OncoAlerts #OncoAlert #CancerAwareness #conferences #Oncology
ipharmacenter.com
BEST SELLING CANCER DRUGS | TOP ONCOLOGY DRUGS | 2025In 2025, global oncology revenues continue to be dominated by immune checkpoint inhibitors and targeted therapies, with Merck’s PD‑1 inhibitor...
0
0
0
#pharma #pharmaceutical #breaking #healthcare #ESMO25 #ASMO25 #SABCS25 #news #media #globalhealth #healthcare #trump
Find the list of top #pharmaceutical companies by revenues in 2025 https://t.co/R1j2nd53jX
#pharma #pharmaceutical #trump #presidenttrump #Medicare #Medicaid #CMS #healthcare #neurology #oncology #rheumatology #SABCS25 #news #media #top10
0
0
0
To find latest #GI25 updates on #Telegram, follow #ipharmacenter by click here https://t.co/aGKASSXegt
#ASCO #ASCOGI25 #ASCOGI2025 #Cancer #Oncology #OncoTwitter #ASCOUpdates #breaking #news #healthcare #pharma #pharmaceutical #HealthForAll
t.me
Find the latest #pharmaceutical and #healthcare #news. Updates from #FDA, #EMA and other healthcare authorities
0
0
0
For any support on competitive intelligence, syndicate reports, pricing and market access, market research projects, please write to info@ipharmacenter.com. #GI25 #ASCO #pharma #pharmaceutical #healthcare #marketaccess
#Gi25 - #Pfizer's Targeted Therapy Shows Promising Results for Metastatic #ColorectalCancer with BRAF V600E Mutation https://t.co/MaPMQHaw7d
#pharma #pharmaceutical #Science #news #media #medicine #DiGiTALhealth #ASCOGI25 #USA #patientcare #healthcare #MedComms #MedicalAffairs
0
0
0
For any support on competitive intelligence, syndicate reports, pricing and market access, market research projects, please write to info@ipharmacenter.com. #GI25
#BMS Unveils Promising Results from CheckMate -8HW Trial on Opdivo + Yervoy Combo for Metastatic Colorectal #Cancer
https://t.co/MaPMQHaw7d
#pharma #pharmaceutical #Science #news #media #medicine #DiGiTALhealth #ASCOGI25 #USA #patientcare #healthcare #MedComms #MedicalAffairs
0
0
0
For any support on competitive intelligence, syndicate reports, pricing and market access, market research projects, please write to info@ipharmacenter.com. #GI25
#Gi25 - #Pfizer's Targeted Therapy Shows Promising Results for Metastatic #ColorectalCancer with BRAF V600E Mutation https://t.co/MaPMQHaw7d
#pharma #pharmaceutical #Science #news #media #medicine #DiGiTALhealth #ASCOGI25 #USA #patientcare #healthcare #MedComms #MedicalAffairs
0
0
0
#India lost to #China in economic growth between 2004-14, but consistently outpacing China in economic growth since 2014. To know more subscribe to our #youtube channel https://t.co/8F3RgzrCyS
#RepublicDay #JanaNayagan #JaiHind ##गणतंत्र_दिवस #Constitution #KartavyaPath
0
6
6
#China Approves #GSK’s #Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults https://t.co/g61JHsm7hV
#pharma #pharmaceutical #healthcare #HMPV #lockdown #chinese #製藥 #衛生保健 #製藥 #消息 #中國 #breaking #news #media #medicine #BreakingNews #PublicHealth #Science
ipharmacenter.com
Nucala has become the first anti-interleukin-5 therapy approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP) that cannot be controlled by standard treatments....
0
7
6
#Vyloytm (zolbetuximab) Gains Approval in #China for 1L Treatment of GEJ Adenocarcinoma https://t.co/mT2fnNo8MQ
#pharma #pharmaceutical #healthcare #HMPV #lockdown #chinese #製藥 #衛生保健 #製藥 #消息 #中國 #breaking #news #media #medicine #BreakingNews #PublicHealth #Science
ipharmacenter.com
China’s National Medical Products Administration (NMPA) has approved Vyloytm (zolbetuximab) for use alongside fluoropyrimidine- and platinum-based chemotherapy as a first-line treatment for adults...
0
6
6
#ValoHealth and #NovoNordisk Expand Partnership to Develop Treatments for #Cardiometabolic Diseases https://t.co/v7TJoZ4RgW
#pharma #pharmaceutical #obesity #weightmanagement #HealthForAll #news #media #medicine #breakingnews #breaking
0
6
6
#Breaking: Vyloytm (zolbetuximab) Gains Approval in #China for 1L Treatment of GEJ Adenocarcinoma https://t.co/hq6QZsZ5ue
#pharma #pharmaceutical #healthcare #HMPV #lockdown #chinese #製藥 #衛生保健 #製藥 #消息 #中國 #news #media #medicine #BreakingNews #PublicHealth #Science
0
6
6
Find our #healthcare & #pharmaceutical consulting services on #fiverr
https://t.co/Z08SBAboSV
#pharma #pharmaceutical #Science #TeleMedicine #news #media #medicine #digitalhealth #breakingnews #marketaccess #patientcare #healthcare #MedComms #MedicalAffairs #Medical #Patientcare
fiverr.com
I am a healthcare consultant who can provide services for the following - Competitive Intelligence - Market research reports - Market access strategies -
#Amgen shares Ph 3 results of #Uplizna in generalized #myastheniagravis (gMG) at #AANEM2024 The trial reached its primary objective, showing a statistically significant improvement in MG-ADL score with Uplizna (-4.2) versus placebo (-2.2) at Week 26 https://t.co/twRl7Emltw
#news
0
0
0
Find our #healthcare & #pharmaceutical consulting services on #fiverr
https://t.co/Z08SBAboSV
#pharma #pharmaceutical #Science #TeleMedicine #news #media #medicine #digitalhealth #breakingnews #marketaccess #patientcare #healthcare #MedComms #MedicalAffairs #Medical #Patientcare
fiverr.com
I am a healthcare consultant who can provide services for the following - Competitive Intelligence - Market research reports - Market access strategies -
Find our #healthcare & #pharmaceutical #consulting services on #fiverr
https://t.co/yk94ymcNDC You can also write to info@ipharmacenter.com Our services include #Competitiveintelligence #AANEM2024 #Marketresearch #Marketaccess #Forecasting #news #media #pharma #freelance
0
0
0
#AANEM2024 - #Nipocalimab Shows Long-Term Disease Control in Adolescents with Generalized #MyastheniaGravis in Ph 2/3 Trial https://t.co/3AXwaaDzZi
#pharma #pharmaceutical #Science #news #media #medicine #breaking #AANEMAnnualMeeting #healthcare #MedComms #MedicalAffairs #Medical
1
2
2
Find our #healthcare & #pharmaceutical #consulting services on #fiverr
https://t.co/yk94ymcNDC You can also write to info@ipharmacenter.com Our services include #Competitiveintelligence #Pipelinereports #Marketresearch #Marketaccess #Forecasting #news #media #pharma #freelance
fiverr.com
I am a healthcare consultant who can provide services for the following - Competitive Intelligence - Market research reports - Market access strategies -
0
5
6